Literature DB >> 12475718

Estrogen receptor phosphorylation.

Deborah A Lannigan1.   

Abstract

Estrogen receptor alpha (ERalpha) is phosphorylated on multiple amino acid residues. For example, in response to estradiol binding, human ERalpha is predominately phosphorylated on Ser-118 and to a lesser extent on Ser-104 and Ser-106. In response to activation of the mitogen-activated protein kinase pathway, phosphorylation occurs on Ser-118 and Ser-167. These serine residues are all located within the activation function 1 region of the N-terminal domain of ERalpha. In contrast, activation of protein kinase A increases the phosphorylation of Ser-236, which is located in the DNA-binding domain. The in vivo phosphorylation status of Tyr-537, located in the ligand-binding domain, remains controversial. In this review, I present evidence that these phosphorylations occur, and identify the kinases thought to be responsible. Additionally, the functional importance of ERalpha phosphorylation is discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12475718     DOI: 10.1016/s0039-128x(02)00110-1

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  134 in total

1.  Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand-independent phosphorylation of serine 305.

Authors:  Jason M Held; David J Britton; Gary K Scott; Elbert L Lee; Birgit Schilling; Michael A Baldwin; Bradford W Gibson; Christopher C Benz
Journal:  Mol Cancer Res       Date:  2012-06-05       Impact factor: 5.852

2.  Headway in resistance to endocrine therapy in breast cancer.

Authors:  Yali Xu; Qiang Sun
Journal:  J Thorac Dis       Date:  2010-09       Impact factor: 2.895

3.  Estrogen receptor beta binds Sp1 and recruits a corepressor complex to the estrogen receptor alpha gene promoter.

Authors:  V Bartella; P Rizza; I Barone; D Zito; F Giordano; C Giordano; S Catalano; L Mauro; D Sisci; M L Panno; S A W Fuqua; S Andò
Journal:  Breast Cancer Res Treat       Date:  2012-05-24       Impact factor: 4.872

4.  ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer.

Authors:  Mary M Heckler; Hemang Thakor; Cara C Schafer; Rebecca B Riggins
Journal:  FEBS J       Date:  2014-04-28       Impact factor: 5.542

5.  Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells.

Authors:  Chun Chen; William T Baumann; Robert Clarke; John J Tyson
Journal:  FEBS Lett       Date:  2013-08-28       Impact factor: 4.124

Review 6.  Structural and functional characterization of aromatase, estrogen receptor, and their genes in endocrine-responsive and -resistant breast cancer cells.

Authors:  Hei Jason Chan; Karineh Petrossian; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2015-08-13       Impact factor: 4.292

7.  Prolactin-growth factor crosstalk reduces mammary estrogen responsiveness despite elevated ERalpha expression.

Authors:  Lisa M Arendt; Tara L Grafwallner-Huseth; Linda A Schuler
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

8.  ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment.

Authors:  Hetal Patel; Manikandan Periyasamy; Georgina P Sava; Alexander Bondke; Brian W Slafer; Sebastian H B Kroll; Marion Barbazanges; Richard Starkey; Silvia Ottaviani; Alison Harrod; Eric O Aboagye; Laki Buluwela; Matthew J Fuchter; Anthony G M Barrett; R Charles Coombes; Simak Ali
Journal:  Mol Cancer Ther       Date:  2018-03-15       Impact factor: 6.261

Review 9.  Long-term consequences of estrogens administered in midlife on female cognitive aging.

Authors:  Jill M Daniel; Christine F Witty; Shaefali P Rodgers
Journal:  Horm Behav       Date:  2015-04-25       Impact factor: 3.587

Review 10.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.